Nevisense is an AI-based point-of-care system for the non-invasive evaluation of atypical pigmented lesions. It is the only FDA-approved technology available for early melanoma detection in the US.
Swedish-based Medtech company, SciBase Holding AB (SciBase), has entered into a collaboration agreement with the USA’s Skin and Cancer Institute to advance an AI-driven skin cancer detector - Nevisense. As per the agreement, Nevisense will be piloted in several parts of California.
Nevisense is an AI-based point-of-care system for the non-invasive evaluation of atypical pigmented lesions. It is the only FDA-approved technology available for early melanoma detection in the US. The new features include a streamlined and more efficient workflow to examine atypical pigmented lesions.
With this move, the Skin and Cancer Institute will be the first dermatology practice group in California to bring AI-driven technology to their patients for skin cancer detection. Further, this collaboration aims to bring the benefits of early melanoma detection to a larger patient population.
Additionally, SciBase can expand and establish a coast-to-coast reach that provides patients with access to early melanoma detection technology.
Sharing his views, Dr Daniel Taheri, medical director and CEO of The Skin Cancer Institute Dermatology Group, said, "We are excited to integrate the Nevisense test during routine skin exams in several of our California offices and offer our patients the latest AI-driven technology for the earliest possible detection of melanoma.”
He continued to add that the Skin Cancer Institute is continuously striving to provide life-saving treatments to the patients, thereby delivering enhanced care by leveraging advanced technology.
Founded in 1998, SciBase is a global medical technology company headquartered in Stockholm, Sweden. The company develops and sells instruments for the detection of skin cancer and other skin conditions in Europe and internationally.
Its products include Nevisense and Nevisense Go, which are point-of-care platforms that address the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment.
On the other hand, founded by Dr Daniel Taheri, the Skin and Cancer Institute is a world-renowned dermatology practice group of dermatologists and skin cancer surgeons. The institute aims to increase public awareness of the early signs of skin cancer and improve the ability of medical and non-medical practitioners to recognise and treat skin cancer.
With the growing importance of early detection of cancer, many organisations are coming up with tools to do so. One such instance is of IIT Madras which established CoE for early detection of pancreatic cancer. The data generated by this centre will contribute to creating an India-specific cancer genome database, crucial for identifying and developing early detection biomarkers and understanding drug responses.